Form 8-K Sarepta Therapeutics, For: Oct 01
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/30/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Wedbush Upgrades Sarepta Therapeutic (SRPT) to Outperform; Case Made for Eteplirsen Approval
October 2, 2015 7:45 AM EDTWedbush upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Neutral to Outperform with a price target of $56 after the company presented data in its NDA for eteplirsen including its 12 boy study Phase II data in the context of matched natural history, dystrophin data from a... More
New Sarepta Therapeutic (SRPT) Data Supports Approval, Oppenheimer Says
October 2, 2015 7:03 AM EDTOppenheimer analyst Christopher Marai reiterated an Outperform rating and $45 price target on Sarepta Therapeutic (NASDAQ: SRPT) following yesterday's WMS update.
Mara commented, "Importantly, an independent re-read of the previous Phase-2b (study-201) %-dystrophin positive fiber data is consistent, showing statistically significant increases in dystrophin at... More
Baird Maintains Bullish View on Sarepta Therapeutic (SRPT) Following WMS Update
October 1, 2015 3:44 PM EDTBaird analyst Brian Skorney reiterated an Outperform rating and $47 price target on Sarepta Therapeutic (NASDAQ: SRPT) saying they remain bullish following World Muscle Society update.
Skorney commented, "Sarepta provided a wealth of new data today that is currently under FDA review. Confirmation of... More
